Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.
Level 4 - case-series / case-control
Prospective single-arm physiological clamp study in healthy volunteers without a randomized control group
PubMed 1987794 · doi:10.1152/ajpendo.1991.260.1.E67
What was done
Ten healthy volunteers underwent stepped hyperinsulinemic glucose clamps with targeted glycemic plateaus of 90, 78, 66, 54, and 42 mg/dl. Researchers measured arterialized venous plasma glucose thresholds for counterregulatory hormone release (glucagon, epinephrine, norepinephrine, growth hormone), symptom onset (autonomic vs. neuroglycopenic), and deterioration on cognitive function tests.
What was found
Responses occurred in a stepwise hierarchy: - Counterregulatory hormones activated first: glucagon at 68 ± 1 mg/dl, epinephrine at 68 ± 1 mg/dl, growth hormone at 67 ± 2 mg/dl, and norepinephrine at 65 ± 1 mg/dl. - Autonomic symptoms (anxiety, palpitations, sweating, irritability, tremor) began at a significantly lower threshold: 58 ± 2 mg/dl (P = 0.0001). - Neuroglycopenic symptoms (hunger, dizziness, tingling, blurred vision, difficulty thinking, faintness) and cognitive deterioration occurred at even lower thresholds: 51 ± 3 mg/dl (P = 0.018 vs. autonomic) and 49 ± 2 mg/dl (P = 0.004 vs. autonomic), respectively.
Why it matters
This study defines the classic physiological hierarchy of hypoglycemia defenses in humans, showing that counterregulatory release and autonomic warning symptoms normally engage before cognitive impairment begins.
Limits
The sample size is very small (n = 10) and limited exclusively to healthy volunteers. It does not measure how glycemic thresholds shift in populations with diabetes or recurrent hypoglycemia-associated autonomic failure.
Cited by
- context In the medical literature, 70 mg/dL (3.9 mmol/L) is typically defined as the threshold for hypoglycemia because the majority of individuals experience symptoms at or below that level.